MQV: Filler, Bone Void, Calcium Compound

Product code MQV, “Filler, Bone Void, Calcium Compound” in FDA's classification database, is a Class II device type under 21 CFR 888.3045 (resorbable calcium salt bone void filler device), reviewed by FDA's Orthopedic panel. FDA's 510(k) database lists 493 clearances under MQV, 236 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
MQV
Regulation
21 CFR 888.3045
Class
II
Panel
Orthopedic
Clearances
493
Most recent
Sep 11, 2026
Median review, last 2 years
93 days
Third-party review
Not eligible
Implant
Yes

What it covers

A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.

The identification in 21 CFR 888.3045, resorbable calcium salt bone void filler device. FDA gives MQV no definition of its own, so the regulation’s describes it.

FDA flags MQV devices as implants.

Recent clearances

510(k)DeviceApplicantDecisionType
K262230Mg OSTEOREVIVE™;Mg OSTEOCRETE™Bone Solutions, Inc.Sep 11, 2026Traditional
K260364Device 300419 StripGeistlich Pharma AGJun 2, 2026Traditional
K252797JAZBI™ Resorbable Bone Void FillerSdip Innovations Pty, Ltd.May 26, 2026Traditional
K261008Vitoss® BiModal Bioactive Bone Graft Substitute Foam Strip; Vitoss® BiModal Bioactive Bone Graft Substitute; Vitoss BBTrauma® Bioactive Bone Graft Substitute; Vitoss® BA2X Bioactive Bone Graft Substitute; Vitoss® Bioactive Foam Bone Graft Substitute Pack; Vitoss® Bioactive Foam Bone Graft Substitute; Vitoss® Foam Bone Graft Substitute; Vitoss® Bone Graft Substitute Filled Canister; Vitoss® Bone Graft SubstituteStryker SpineApr 24, 2026Special
K253524Adaptos®Fuse Bone GraftBiomendex OYFeb 17, 2026Traditional
K253147FIBERGRAFT™ BG Putty GPS Bone Graft Substitute FIBERGRAFT™ BG Putty Bone Graft Substitute FIBERGRAFT™ AERIDYAN™ Matrix Bone Graft Substitute FIBERGRAFT™ BG Matrix Bone Graft SubstituteProsidyan, Inc.Oct 22, 2025Special
K251522Mg OSTEOINJECT™; Mg OSTEOREVIVE™; Mg OSTEOCRETE™Bone Solutions, Inc.Oct 13, 2025Traditional
K252085Allomatrix (Allomatrix Injectable Putty; Allomatrix C; Allomatrix DR; Allomatrix Custom)Wright Medical Technology, Inc. (Stryker Corporation)Sep 30, 2025Traditional
K251556Device 300423 GranulesGeistlich Pharma AGJul 17, 2025Traditional
K251720OsteoFlo HydroFiberSurGenTec, LLCJul 2, 2025Special
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 493 with a free account)

Clearances by year

236 MQV 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
2026 (so far)596
20251457
20242855
20232174
20229118
2021888
202015132
20191390
201823124
201717124
20168214
201518184
201420153
201312197
20129107
20111692

Who submits

102 applicants cleared a MQV device since 2011. 76% of the clearances went to applicants in United States, then Netherlands (6%), United Kingdom (3%) and Taiwan (3%). By type: Traditional 85% and Special 15%.

ApplicantClearances since 2011
Kuros Biosciences B.V11
Prosidyan, Inc.10
Novabone Products, LLC9
Wrightmedicaltechnologyinc9
Baxter Healthcare Corporation7
Orthocon, Inc.7
SeaSpine Orthopedics Corporation7
Bone Solutions, Inc.6

How FDA classifies it

Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.

From 21 CFR 888.3045. Special controls are the requirements a 510(k) must show it meets.

Standards

21 CFR 888.3045 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent MQV clearances declared.

Ask about MQV

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about MQV

What is FDA product code MQV?

Product code MQV, “Filler, Bone Void, Calcium Compound” in FDA's classification database, is a Class II device type under 21 CFR 888.3045 (resorbable calcium salt bone void filler device), reviewed by FDA's Orthopedic panel. FDA's 510(k) database lists 493 clearances under MQV, 236 of them since 2011.

How many 510(k) clearances are there under MQV?

FDA’s 510(k) database listed 493 clearances under MQV as of Oct 29, 2026, 236 of them decided since 2011; the most recent decision was Sep 11, 2026. The Predicate Finder searches the live database.

How long does FDA take to clear a MQV 510(k)?

For the 28 MQV clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 93 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most MQV clearances?

Since 2011: Kuros Biosciences B.V (11), Prosidyan, Inc. (10), Novabone Products, LLC (9), Wrightmedicaltechnologyinc (9) and Baxter Healthcare Corporation (7). 102 applicants have cleared a MQV device in that time.

Sources

  1. FDA product classification: MQV · Product Classification database
  2. 21 CFR 888.3045: Resorbable calcium salt bone void filler device · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for MQV · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow MQVGet an email when FDA clears, recalls or publishes guidance for MQV devices.

Know what FDA already cleared.